ATE271863T1 - Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren - Google Patents
Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahrenInfo
- Publication number
- ATE271863T1 ATE271863T1 AT96938414T AT96938414T ATE271863T1 AT E271863 T1 ATE271863 T1 AT E271863T1 AT 96938414 T AT96938414 T AT 96938414T AT 96938414 T AT96938414 T AT 96938414T AT E271863 T1 ATE271863 T1 AT E271863T1
- Authority
- AT
- Austria
- Prior art keywords
- preparations
- disclosed
- thyroid hormones
- drugs
- preparation
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000005495 thyroid hormone Substances 0.000 title abstract 2
- 229940036555 thyroid hormone Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 abstract 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
- 229930182830 galactose Natural products 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 229940034208 thyroxine Drugs 0.000 abstract 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US673895P | 1995-11-14 | 1995-11-14 | |
US1731496P | 1996-05-13 | 1996-05-13 | |
PCT/IB1996/001330 WO1997017951A1 (en) | 1995-11-14 | 1996-11-14 | Stabilized thyroid hormone preparations and methods of making same |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE271863T1 true ATE271863T1 (de) | 2004-08-15 |
Family
ID=26675995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96938414T ATE271863T1 (de) | 1995-11-14 | 1996-11-14 | Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren |
Country Status (12)
Country | Link |
---|---|
US (2) | US5955105A (de) |
EP (1) | EP0861073B1 (de) |
JP (1) | JP2000500155A (de) |
AT (1) | ATE271863T1 (de) |
AU (1) | AU712217B2 (de) |
BR (1) | BR9611306A (de) |
CA (1) | CA2235707A1 (de) |
DE (1) | DE69633018T2 (de) |
ES (1) | ES2224184T3 (de) |
MX (1) | MXPA98003802A (de) |
PT (1) | PT861073E (de) |
WO (1) | WO1997017951A1 (de) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19821625C1 (de) * | 1998-05-15 | 2000-01-05 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
DE19830246A1 (de) * | 1998-07-07 | 2000-01-13 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
JP2002540073A (ja) * | 1999-03-10 | 2002-11-26 | ロータス バイオケミカル コーポレイション | 化学化合物の保護および放出のためのタンパク質コンホメーションの使用 |
NZ517466A (en) * | 1999-09-02 | 2003-11-28 | Nostrum Pharmaceuticals Inc | Controlled release oral dosage suitable for oral administration |
US6627660B1 (en) * | 1999-11-16 | 2003-09-30 | New River Pharmaceuticals Inc. | Stabilized thyroxine compounds |
US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US6399101B1 (en) | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
ES2461196T3 (es) | 2000-05-24 | 2014-05-19 | Otsuka Pharmaceutical Co., Ltd. | Procedimiento para estabilizar una preparación |
EP1157682A1 (de) * | 2000-05-25 | 2001-11-28 | Cilag AG | Blisterpackung für Topiramattabletten |
US6855333B1 (en) * | 2000-10-03 | 2005-02-15 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid thyroid drug formulations |
US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
KR20040100835A (ko) * | 2001-02-15 | 2004-12-02 | 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 | 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법 |
US20030224047A1 (en) * | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
GB0113841D0 (en) * | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
ITMI20011401A1 (it) * | 2001-07-02 | 2003-01-02 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei |
US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
US20030194436A1 (en) * | 2001-08-10 | 2003-10-16 | Franz Andrew G. | Immediate release pharmaceutical compositions |
US20030199585A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G Andrew | Levothyroxine compositions and methods |
US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
AU2002332507A1 (en) * | 2001-08-10 | 2003-02-24 | King Pharmaceuticals, Inc. | Levothyroxine compositions and methods |
US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
US7101569B2 (en) * | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
WO2003061557A2 (en) * | 2001-08-14 | 2003-07-31 | King Pharmaceuticals, Inc. | Levothyroxine pharmaceutical compositions, methods of making and methods of administration |
US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
US20030199587A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique Cmax properties |
US20030199586A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Unique levothyroxine aqueous materials |
US20030194437A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Cmax properties |
US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US20030175337A1 (en) * | 2001-10-29 | 2003-09-18 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
US6645526B2 (en) * | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
US20030099699A1 (en) * | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
PL369972A1 (en) * | 2002-01-07 | 2005-05-02 | Abbott Gmbh & Co.Kg | Crystallization of amino acids using ultrasonic agitation |
AU2003241537A1 (en) * | 2002-05-23 | 2003-12-12 | Andrx Corporation | Biguanide formulations |
WO2004014318A2 (en) * | 2002-08-10 | 2004-02-19 | King Pharmaceuticals, Inc. | Levothyroxine compositions and methods |
US20040152783A1 (en) * | 2002-11-05 | 2004-08-05 | Olon Lawrence Peter | Controlled absorption of admixed thyroid hormone formulations |
ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
US7192944B2 (en) * | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
JP4589919B2 (ja) * | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
ATE406364T1 (de) | 2003-03-07 | 2008-09-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
EP1622587B1 (de) * | 2003-05-02 | 2010-04-28 | Globopharm Pharmazeutische Produktions- und Handelsgesellschaft m.b.H. | Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze |
US8293272B2 (en) * | 2003-05-02 | 2012-10-23 | Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts |
GB0316206D0 (en) * | 2003-07-10 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulation |
US20060008512A1 (en) * | 2004-07-07 | 2006-01-12 | Hooge Danny M | Composition and methods for improved animal performance |
ATE519480T1 (de) * | 2006-01-06 | 2011-08-15 | Intervet Int Bv | Konzentrierte flüssige schilddrüsenhormonzusammensetzung |
US7858663B1 (en) | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
GB2457710A (en) * | 2008-02-25 | 2009-08-26 | Andrew Nicolaou | Thyroxine and its use in weight loss and obesity treatment |
IT1395454B1 (it) * | 2009-03-24 | 2012-09-21 | Altergon Sa | Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale |
EP2248518B1 (de) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulierung zur Stabilisierung von Proteinen, Peptiden und deren Mischungen. |
CA2805958A1 (en) * | 2009-08-04 | 2011-02-10 | Haren Treasurer | Greater utility with thyroid hormone |
ES2639617T3 (es) | 2010-10-12 | 2017-10-27 | Merz Pharma Gmbh & Co. Kgaa | Formulación adecuada para estabilizar proteínas, que carece de excipientes de mamíferos |
AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
CN107840813B (zh) * | 2011-04-08 | 2020-12-22 | 伯拉考成像股份公司 | 用于制备3,5-二碘-o-[3-碘苯基]-l-酪氨酸的硫酸化衍生物的方法 |
US9006289B2 (en) * | 2011-08-30 | 2015-04-14 | Fresenius Kabi Usa, Llc | Levothyroxine formulations |
US8779000B1 (en) * | 2013-07-20 | 2014-07-15 | Nilesh Parikh | Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production |
EP2932963A1 (de) | 2014-04-16 | 2015-10-21 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Stabile pharmazeutische Darreichungsformen enthaltend Levothyroxine Natrium |
WO2017013591A1 (en) | 2015-07-22 | 2017-01-26 | Leiutis Pharmaceuticals Pvt Ltd | Stabilized liquid formulation of levothyroxine |
GB2558498B (en) | 2015-11-04 | 2020-10-14 | Leiutis Pharm Pvt Ltd | Novel levothyroxine formulations for oral use |
NL2017110B1 (en) * | 2016-07-05 | 2018-01-12 | Emp Levo Gmbh | Methods for the preparation of a levothyroxine solution |
US10231931B1 (en) | 2018-03-23 | 2019-03-19 | Genus Lifesciences Inc. | Thyroid hormone oral dosage forms and methods of using the same |
TW202227047A (zh) * | 2020-10-09 | 2022-07-16 | 日商Aska製藥股份有限公司 | 甲狀腺荷爾蒙的製劑化方法 |
WO2023088976A1 (en) | 2021-11-16 | 2023-05-25 | Tap Pharmaceuticals, Ag | Orodispersible levothyroxine compositions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
CH658188A5 (de) * | 1984-03-23 | 1986-10-31 | Ciba Geigy Ag | Lagerstabile schnellzerfallende pharmazeutische presslinge. |
US4851228A (en) * | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US5102666A (en) * | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
US5275820A (en) * | 1990-12-27 | 1994-01-04 | Allergan, Inc. | Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles |
US5225204A (en) * | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
ATE164063T1 (de) * | 1991-12-30 | 1998-04-15 | Akzo Nobel Nv | Thyroaktive zusammensetzung mit kontrollierter freigabe |
DE4318577A1 (de) * | 1993-06-04 | 1994-12-08 | Merck Patent Gmbh | Schmiermittelfreie, arzneimittelhaltige Tabletten |
GB9401879D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
GB9401892D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
HUT75956A (en) * | 1995-11-29 | 1997-05-28 | Cyclolab | Pharmaceutical composition containing thyroxine |
-
1996
- 1996-11-14 CA CA002235707A patent/CA2235707A1/en not_active Abandoned
- 1996-11-14 MX MXPA98003802A patent/MXPA98003802A/es unknown
- 1996-11-14 WO PCT/IB1996/001330 patent/WO1997017951A1/en active IP Right Grant
- 1996-11-14 US US08/748,869 patent/US5955105A/en not_active Expired - Lifetime
- 1996-11-14 EP EP96938414A patent/EP0861073B1/de not_active Expired - Lifetime
- 1996-11-14 ES ES96938414T patent/ES2224184T3/es not_active Expired - Lifetime
- 1996-11-14 AU AU75849/96A patent/AU712217B2/en not_active Ceased
- 1996-11-14 AT AT96938414T patent/ATE271863T1/de not_active IP Right Cessation
- 1996-11-14 JP JP9518710A patent/JP2000500155A/ja not_active Ceased
- 1996-11-14 BR BR9611306-5A patent/BR9611306A/pt not_active Application Discontinuation
- 1996-11-14 DE DE69633018T patent/DE69633018T2/de not_active Expired - Fee Related
- 1996-11-14 PT PT96938414T patent/PT861073E/pt unknown
-
1998
- 1998-09-18 US US09/156,844 patent/US6056975A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU7584996A (en) | 1997-06-05 |
PT861073E (pt) | 2004-10-29 |
DE69633018D1 (de) | 2004-09-02 |
US5955105A (en) | 1999-09-21 |
MXPA98003802A (es) | 2005-04-29 |
EP0861073B1 (de) | 2004-07-28 |
US6056975A (en) | 2000-05-02 |
JP2000500155A (ja) | 2000-01-11 |
BR9611306A (pt) | 1999-12-28 |
WO1997017951A1 (en) | 1997-05-22 |
ES2224184T3 (es) | 2005-03-01 |
DE69633018T2 (de) | 2004-12-09 |
CA2235707A1 (en) | 1997-05-22 |
AU712217B2 (en) | 1999-11-04 |
EP0861073A1 (de) | 1998-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE271863T1 (de) | Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren | |
KR910015298A (ko) | 오메프라졸 직장투여조성물 | |
CA2033725A1 (en) | Pharmaceutical and cosmetic compositions containing a salt of cholanic acid | |
BG101781A (en) | Active substance-containing solid preparation | |
HUP0004924A2 (hu) | Ciklodextrineket tartalmazó gyógyászati készítmények | |
AU7038587A (en) | Amino acid chelated compositions | |
HUP0000589A2 (hu) | Vizes peptid készítmények | |
ATE83924T1 (de) | Ibuprofen-cyclodextrin-einschlusskomplexe enthaltende pharmazeutische zubereitungen. | |
HUP9802287A2 (hu) | Cinkkel és kívánt esetben lizinnel vagy kalciumionnal előkezelt növekedési hormont tartalmazó stabilizált gyógyszerkészítmény | |
EP0787497A3 (de) | Humanes Wachstumshormon enthaltendes pharmazeutisches Präparat | |
IL94433A0 (en) | Aminophenol derivatives,their preparation and pharmaceutical compositions containing them | |
AU678344B2 (en) | Lipophilic oligosaccharide antibiotic salt compositions | |
ATE220321T1 (de) | Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe | |
KR900013964A (ko) | 활성형 비타민 d₃류 제제용 조성물 및 이를 함유하는 안정한 활성형 비타민 d₃류 제제의 제조방법 | |
ID22763A (id) | Komposisi penstabil tibolon | |
AU7683296A (en) | Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them | |
KR900014406A (ko) | 세펨 화합물 및 이의 제조방법 | |
AU566228B2 (en) | Compressed hydroxybutryic acid polymer retarded release vehicle | |
FR2380782A1 (fr) | Fraction 5 de thymosine stabilisee utile comme medicament et procede pour la preparer | |
IL83086A0 (en) | Stable,injectable solutions of vinca dimer salts | |
FI941399A0 (fi) | Sparfloksasiiniliuos, sen valmistus ja sitä sisältävä suola | |
UA40636C2 (uk) | Фармацевтична композиція для одержання стабільного порошку, яка містить як активний компонент асоціацію ацетилсаліцилової кислоти та метоклопраміду, фармацевтичний препарат у формі порошку та спосіб одержання цього препарату | |
NZ331083A (en) | Pharmaceutical preparations of cilansetron stabilized against racemization | |
JPS5781409A (en) | External plaster | |
ZA91115B (en) | Topical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0861073 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |